Lung Ultrasound Guided Fluid Removal for Acute Heart Failure Patients
Compares lung ultrasound-guided fluid removal with physical examination in adults hospitalized for acute heart failure.
Plain-language title generated from the registry record
Registry title: Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
Key facts
- Where
- Bern, Fribourg, Geneva, and Lugano, SwitzerlandSee the 5 sites
Where in Switzerland
- Inselspital, UniversitätspitalBern, SwitzerlandTaking people
- Fribourg University HospitalFribourg, SwitzerlandTaking people
- Geneva University HospitalsGeneva, SwitzerlandTaking people
- Trois-Chêne Hospital, Geneva Univesity HospitalsGeneva, SwitzerlandTaking people
- Ospedale Civico, Ente Ospedaliero CantonaleLugano, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Antonio Leidi
- Trial code
- NCT06465498
- Record updated
- 1 April 2026
- Original description
The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes.Read full original descriptionShow less
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography (IcarUS) : a Randomized Controlled Trial
The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes.
The main questions it aims to answer are:
* Does this strategy shorten the length of stay and reduce early hospital readmissions? * Does this strategy improve patients' symptoms and quality of life ?
Researchers will compare LUS to physical examination (PE).
Inclusion: ≥ 18 years old; Planned or actual admission to intermediate care units, general internal medical or cardiology wards; Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis); Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l).
Exclusion: Known isolated right heart failure; The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion; Systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg at the moment of inclusion; Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months; Unwillingness to give consent; Subjects who are pregnant or breastfeeding; Hospitalisation for palliative care and probable end-life within 30 days.